Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

Jörg Schubert, MD, Peter Hillmen, MB, PhD, Ulrich Dührsen, DM, Neal S. Young, MD, Modupe Elebute, MB, MD, Jeffrey Szer, MB, BS, Giacomo Gianfaldoni, MD, Gérard Socié, MD, PhD, Paul Browne, MD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Petra Muus, MD, PhD

Blood (2006) 108 (11): 124.

https://doi.org/10.1182/blood.V108.11.124.124

Published: 2006

Journal Articles

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Neal S. Young, MD, Elisabetta Antonioli, MD, Bruno Rotoli, MD, Hubert Schrezenmeier, MD, Jörg Schubert, MD, Alvaro Urbano-Ispizua, MD, Luke Coyle, MD, Carlos de Castro, MD, Chieh-Lin Fu, MD, Jaroslaw P. Maciejewski, MD, PhD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Peter Hillmen, MB PhD

Blood (2006) 108 (11): 971.

https://doi.org/10.1182/blood.V108.11.971.971

Published: 2006

Journal Articles

Successful Treatment of Hemolysis and Severe Anemia without Transfusion in a Jehovah’s Witness PNH Patient with the Terminal Complement Inhibitor Eculizumab.

Robert M. Glasser, MD, Christopher F. Mojcik, MD, PhD

Blood (2005) 106 (11): 3768.

https://doi.org/10.1182/blood.V106.11.3768.3768

Published: 2005

Journal Articles

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

Anita Hill, Peter Hillmen, Stephen J. Richards, Dupe Elebute, Judith C. Marsh, Jason Chan, Christopher F. Mojcik, Russell P. Rother

Blood (2005) 106 (7): 2559–2565.

https://doi.org/10.1182/blood-2005-02-0564

Published: 2005

Journal Articles

Vascular Cell Adhesion Molecule-1 Is Expressed by Cortical Thymic Epithelial Cells and Mediates Thymocyte Adhesion. Implications for the Function of α4β1 (VLA4) Integrin in T-Cell Development

Daniel R. Salomon, Laura Crisa, Christopher F. Mojcik, Jennifer K. Ishii, George Klier, Ethan M. Shevach

Blood (1997) 89 (7): 2461–2471.

https://doi.org/10.1182/blood.V89.7.2461

Published: 1997

NARROW

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Successful Treatment of Hemolysis and Severe Anemia without Transfusion in a Jehovah’s Witness PNH Patient with the Terminal Complement Inhibitor Eculizumab.

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

Vascular Cell Adhesion Molecule-1 Is Expressed by Cortical Thymic Epithelial Cells and Mediates Thymocyte Adhesion. Implications for the Function of α4β1 (VLA4) Integrin in T-Cell Development

Email alerts

ASH Publications

American Society of Hematology

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Successful Treatment of Hemolysis and Severe Anemia without Transfusion in a Jehovah’s Witness PNH Patient with the Terminal Complement Inhibitor Eculizumab.

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

Vascular Cell Adhesion Molecule-1 Is Expressed by Cortical Thymic Epithelial Cells and Mediates Thymocyte Adhesion. Implications for the Function of α4β1 (VLA4) Integrin in T-Cell Development

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only